Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | NEJM
Advancing Precision Medicine: In Vitro Potency Assays for Evaluating the Function of anti-PD-1 Checkpoint Inhibitors
PD-1: Expanding Beyond Cancer Research | ProSci
Biomarkers of response to PD-1 pathway blockade | British Journal of Cancer
Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles | Nature Communications
Learning from PD-1 Resistance: New Combination Strategies: Trends in Molecular Medicine
Cancer: anti-PD-1 / PD-L1 antibodies, new solutions for immunotherapy
Anti-hPD-1 antibodies | Pembrolizumab & Nivolumab biosimilar isotypes | InvivoGen
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action - Willsmore - 2021 - European Journal of Immunology - Wiley Online Library
PD-1
Frontiers | Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
News
Agonistic anti-PD-1 antibodies turn on the immunosuppressive activity of PD- 1
Schematic representation of PD-1 and anti-PD-1/PD-L1 mechanisms of... | Download Scientific Diagram
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics | Journal of Hematology & Oncology | Full Text
PDL1 e immunoterapici | L'immunologo risponde | alcase.eu
JCM | Free Full-Text | Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer: Molecular Therapy
Frontiers | Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
PD1 Antibody Selection Tool | Bio X Cell
PD-1
A Surprising Match: Cancer Immunotherapy and Mismatch Repair – NIH Director's Blog
Current issues and perspectives in PD-1 blockade cancer immunotherapy | International Journal of Clinical Oncology
